Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.
Jakestar,
Would be keen to hear your own view on why we trade at 108p (lower than prior to commencement of the trial) when Avacta are going to update the market in days confirming positive phase1a data (99.9 probability imo)!
No if, but or maybe, Avacta will update on AVA6K within a matter of days.
The fact they decided to sign post/ tell the market they will update in a matter of days suggests they want all eyes focussed on the next RNS. Certainly not an action one would take if trying to cover any negative news.
I'm not sure that the selected key opinion leaders that will present at the science day will be there to talk solely on AVA6K safety and tolerability... This step (inviting these leaders to discuss the data) points towards positive secondary measures (AVA6k anti tumor activity, biopsy data etc)
Thoughts ?
Luke,
They're there so that the fund managers and potential investors appreciate what is being presented
Exactly. The speakers will be totally neutral to Avacta. Extremely positive sign
Avacta are gearing up to showcase the P1a data
What better way to do so than to include selected key opinion leaders in the field of oncology to discuss the data.
No doubt at all now data will be blockbuster
To my last question (why couldn't Clovis licence prior to bankruptcy) I really have no clue as clearly it has/had a valued asset. But,. What this does confirm is that Avacta recent raise was a masterstroke from perspective of delivering leverage during any ongoing or planned negotiation! There is no bankruptcy or fire sale scheduled here, thus if you want to licence it is on Avacta terms
If the screen/statement was the only 'clue' or 'indication' of positive AVA6K clinical performance I would agree that we could be jumping to conclusions. For all we know, the previous Screenshot stated -we are Avacta and our ambition is-
However, we now have many multiple solid Clues/indications that, when considered together, makes the probability of positive clinical performance a certainty imo.
Positive clinical performance = 1. Improved safety, 2. Improved Tolerability and 3. Activiation.
If you combine these 3 then Precision is blockbuster.